

Gilead Sciences Appoints Two New Members to Health Policy Advisory Board

June 6, 2012 8:31 AM ET

– Lord Paul Boateng and Dr. Hannah Kettler Will Bring Extensive Experience in Global Health, Health Economics and Humanitarian Issues –

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 6, 2012-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today the appointments of Lord Paul Boateng, LLB, member of the United Kingdom House of Lords, and Hannah Kettler, PhD, senior health program officer and economist at the Bill & Melinda Gates Foundation, to the Gilead Health Policy Advisory Board. The advisory board - comprised of leading experts in their fields - provides external perspective and advice, helping the company shape programs and policies to deliver medications to patients affected by HIV/AIDS, viral hepatitis and other life-threatening diseases around the world.

“I am thrilled that Lord Boateng and Dr. Kettler have joined the Gilead Health Policy Advisory Board,” said Sir Richard Feachem, KBE, FREng, DSc (Med), PhD, chairperson of the advisory board and professor of global health at the University of California, San Francisco, and the University of California, Berkeley. “Their important and unique expertise will contribute greatly to Gilead’s work to address barriers to patient care and ensure that innovative medicines are accessible to all people who need them.”

Lord Boateng was appointed to the U.K. House of Lords in 2010 after serving for four years as the British high commissioner to South Africa. First elected to Parliament in 1987, Lord Boateng held various ministerial posts, including Junior Minister for Health in 1997, before being appointed to the Cabinet as Chief Secretary to the Treasury in 2002, both under former Prime Minister Tony Blair.

A long-time advocate for international health and humanitarian issues, Lord Boateng participated in the drafting of the 2005 Africa Commission report calling on developed countries to increase development aid to Africa. Lord Boateng received his law degree from the University of Bristol.

Dr. Kettler is a senior economist in the Gates Foundation’s Global Health Program, responsible for overseeing a portfolio of grants and projects to foster innovation in new medicines, diagnostics and vaccines for developing countries. Before joining the Gates Foundation, Dr. Kettler led a project on biotechnology and international health at the University of California, San Francisco, and worked as the senior industrial economist for the Office of Health Economics in London. Dr. Kettler received her doctoral degree in industrial economics from the University of Notre Dame.

“Gilead’s role in advancing health begins by innovating in the laboratory and extends to ensuring that patients with life-threatening diseases are able to access care,” said Gregg H. Alton, Gilead’s executive vice president for corporate and medical affairs. “We are grateful for the guidance provided by the Health Policy Advisory Board and enthusiastically welcome Lord Boateng and Dr. Kettler as members.”

About the Gilead Health Policy Advisory Board

The Gilead Health Policy Advisory Board was established in 2007 and meets three times per year. The board provides regular input on issues related to global health policy, access to healthcare and improved healthcare systems, disease prevention and education, intellectual property and trade issues, and health economics and pricing.

In addition to Sir Richard Feachem, current members of the Gilead Health Policy Advisory Board include Seth F. Berkley, MD, CEO of the GAVI Alliance; Michael V. Drake, MD, chancellor of the University of California, Irvine; David Gollaher, PhD, president and CEO of the California Healthcare Institute; Calvin Pan, MD, associate clinical professor at Mount Sinai School of Medicine; Robert Shapiro, PhD, chairman of Sonecon, LLC; Richard J. Whitley, MD, professor of medicine and microbiology at the University of Alabama at Birmingham; and Per Wold-Olsen, former president of the Human Health Intercontinental Division of Merck & Co., Inc. Board members are appointed for two-year terms and serve in their individual capacities.

Richard Whitley, MD, and Per Wold-Olsen are also members of the Gilead Board of Directors.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.

Nick Francis, +44 208 587 2412 (Media)

Amy Flood, 650-522-5643 (Media)